Your session is about to expire
← Back to Search
Vitamin
High-Dose Folic Acid Supplementation for Metabolic Health During Pregnancy
N/A
Waitlist Available
Led By Yvonne Lamers, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Must not have
Unable to swallow tablets
Unable to receive intravenous catheters
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial compares synthetic folic acid and natural 5-MTHF to see how they affect nutrient processing in healthy people. It uses special tracking methods to observe these changes and considers genetic differences in a key enzyme. 5-MTHF is a natural form of folate that is well absorbed and more bioavailable than synthetic folic acid, even in individuals with metabolic defects.
Who is the study for?
This trial is for generally healthy individuals with a BMI of 19-24 kg/m2 and normal levels of folate, vitamin B12, and B6. It's not for those who've used certain supplements recently, have chronic diseases like diabetes or asthma, are pregnant or breastfeeding, smoke, use drugs, drink heavily, can't swallow pills or consent in English.
What is being tested?
The study compares the effects of high-dose folic acid versus a natural form called 5-MTHF on DNA-related cellular mechanisms in humans. Researchers will track how these substances influence metabolic pathways using stable isotope tracer protocols.
What are the potential side effects?
While specific side effects aren't listed for this trial due to the nature of the substances being vitamins at presumably safe doses, potential general side effects could include allergic reactions or gastrointestinal discomfort.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I cannot swallow pills.
Select...
I cannot have IV lines inserted.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Folic acid supplementationExperimental Treatment1 Intervention
Folic acid will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.
Group II: 5-MTHF supplementationExperimental Treatment1 Intervention
The calcium salt of 5-methyltetrahydrofolate (5-MTHF; Brand name "Metafolin") will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Folic acid
2008
Completed Phase 4
~8330
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Folic acid, a synthetic form of folate, plays a critical role in One-Carbon Metabolism by aiding in the synthesis of nucleotides and the remethylation of homocysteine to methionine, which are essential for DNA synthesis and repair. High-dose folic acid supplementation can alter the turnover rate of folate-dependent pathways, impacting cellular functions and overall metabolic health.
This is particularly important for patients with One-Carbon Metabolism disorders, as it helps manage conditions like hyperhomocysteinemia and supports overall cellular health.
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,465 Previous Clinical Trials
2,485,472 Total Patients Enrolled
Yvonne Lamers, PhDPrincipal InvestigatorUniversity of British Columbia
2 Previous Clinical Trials
390 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I cannot swallow pills.I cannot have IV lines inserted.I have a chronic condition like diabetes, asthma, or heart disease.I do not smoke, use recreational drugs, or drink more than one alcoholic beverage daily or seven weekly.I am on long-term medication like birth control, antidepressants, or blood thinners.
Research Study Groups:
This trial has the following groups:- Group 1: Folic acid supplementation
- Group 2: 5-MTHF supplementation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger